According to the recently published report Midkine – Pipeline Review, H1 2018 Midkine (Amphiregulin Associated Protein or Midgestation and Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.
Midkine (Amphiregulin Associated Protein or Midgestation and Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) – Midkine (MDK) or neurite growth-promoting factor 2 is a protein encoded by the MDK gene. It binds to anaplastic lymphoma kinase which induces ALK activation and subsequent phosphorylation of the insulin receptor substrate, activation of mitogen-activated protein kinase and PI3-kinase and the induction of cell proliferation. It is involved in neointima formation after arterial injury and early fetal adrenal gland development.
The report ‘Midkine – Pipeline Review, H1 2018’ outlays comprehensive information on the Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Midkine (Amphiregulin Associated Protein or Midgestation and Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, the molecules developed by companies in Preclinical stages are 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Gastrointestinal, Musculoskeletal Disorders, Cardiovascular and Respiratory which include indications Inflammation, Diabetic Nephropathy, Kidney Fibrosis, Liver Fibrosis, Non-Small Cell Lung Cancer, Acute Renal Failure (ARF) (Acute Kidney Injury), Autoimmune Disorders, Bone Disorders, Bone Fracture, Chronic Kidney Disease (Chronic Renal Failure), Fibrosis, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Glomerulonephritis, Ischemia Reperfusion Injury, Kidney Disease, Lung Disease, Neuroblastoma, Osteoporosis, Osteosarcoma, Prostate Cancer, Solid Tumor and Squamous Non-Small Cell Lung Cancer.
The report provides a snapshot of the global therapeutic landscape for Midkine (Amphiregulin Associated Protein or Midgestation and Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK)
The report reviews Midkine (Amphiregulin Associated Protein or Midgestation and Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Midkine (Amphiregulin Associated Protein or Midgestation and Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics and enlists all their major and minor projects
The report assesses Midkine (Amphiregulin Associated Protein or Midgestation and Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Midkine (Amphiregulin Associated Protein or Midgestation and Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics
To know, more click on the link below:
Related Reports:
https://www.kenresearch.com/healthcare/pharmaceuticals/midkine-amphiregulin-associated/49986-91.html
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
0124-4230204
